Medical Isotope Production Companies
.png)
Published: September 2026
Medical isotopes are specific radioactive elements that are used extensively in clinics and hospitals for the diagnosis as well as treatment of various diseases. Medical isotopes can be stable as well as radioactive in nature. With the help of detectable radiation emissions, they act as tracers to recognize and destroy cancer cells and work with precision.
A medical isotope production company manufactures radioactive materials which are used in targeted cancer therapies and diagnostic techniques. These companies rely on highly specialized supply chains using accelerators, nuclear reactors, chemical separation and other methods.
The Medical Isotopes nuclear medicine sector continues to expand rapidly by leveraging innovations in medical isotope chemistry, production methods, and purification technologies to refine safety and efficacy profile. In terms of key market drivers, increasing demands for targeted alpha therapies, rapid surge in the number of cancer cases and new advancements in accelerator technologies are contributing to the overall Medical Isotope Production market. Leading global producers use different production methods for the supply of critical diagnostic tracers like technetium-99m and other therapeutic isotopes including actinium-225 and lutetium-177.
Roots Analysis has conducted an exhaustive study on featuring the current market landscape and future opportunities for companies engaged in healthcare, over a span of next 10 years.
Top Twelve Leading Medical Isotope Production Companies
- ABX advanced biochemical compounds
- Cardinal Health
- China Isotope & Radiation Corporation
- CMR Isotopes
- Curium Pharma
- Eckert & Ziegler
- Eden Radioisotopes
- Global Medical Solutions
- Northstar Medical Radioisotopes
- Nusano
- ROTOP Pharmaka
- SpectronRx
The figure below highlights the top twelve medical isotope production companies:
Interested in exploring all ~110 players offering medical isotope production services, along with their recent initiatives?
Discover Below the Details of 12 leading Medical Isotope Production Companies
Let us dive deep into the details of the twelve leading medical isotope production companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. ABX advanced biochemical compounds
Company Overview
ABX advanced biochemical compounds specializes in manufacturing innovative radiopharmaceutical kits and cassettes, leveraging in-house hot lab facilities for research and development to support its own operations and those of other pharmaceutical firms. The company produces essential building blocks for all types of radiopharmaceuticals, with comprehensive capabilities spanning positron emission tomography, and single-photon emission computed tomography precursors, reagent kits, and full-scale GMP drug manufacturing. Minimally reliant on external suppliers, ABX maintains self-sufficiency through in-house production of sterile disposables and aseptic excipients. Its team of organic and medicinal chemistry experts harnesses state-of-the-art labs to develop targeted compounds for medical isotope applications.
ABX advanced biochemical compounds: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| ABX advanced biochemical compounds | 1997 | Germany | 201-500 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by ABX advanced biochemical compounds, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| ABX advanced biochemical compounds | Copper-61 / 64 / 67, Gallium-67 / 68, Lutetium-177, Technetium-99, Yttrium-90 / 176, Zirconium-89, and Others | Carbon-11 / 14, Fluorine-18, and Iodine-121 / 123 / 124 / 125 / 131 | Stable isotope and Radioisotope | Accelerator and Others | Diagnostic Imaging, Therapeutic Application, and Research and Development | Diagnostic Centers, Hospitals, and Academic and Research Institutes |
Recent Developments
In January 2026, the company announced the approval of a funding notice by EU and free state of Saxony to support the soil remediation project leading to site expansion. The company also expanded its facilities by becoming a member of the new radio pharmacy cluster Dresden.
To know more about the recent initiatives of ABX advanced biochemical compounds and other medical isotope production companies, access full report.
2. Cardinal Health
Company Overview
Cardinal Health is a leading distributor of pharmaceuticals and specialty products, supplier of home-health and direct-to-patient solutions, operator of nuclear pharmacies and manufacturing facilities focused on medical isotope in medicine, provider of performance and data solutions. Through these segments they act as healthcare’s most trusted partner, safely delivering essential products to improve daily lives. The company bridges nuclear innovators and manufacturers with biopharma innovators, generic Rx makers, consumer health firms, and medical-surgical producers on the supply side, while connecting them to retail/grocery pharmacies, mail-order pharmacies, health systems, specialty physician offices home patients, and government entities on the demand side. Their expertise and portfolio of safe, effective isotopes enhance quality meet demands for value-driven nuclear medicine solutions in diagnostics and therapy.
Cardinal Health: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Cardinal Health | 1971 | US | 10,000+ |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by Cardinal Health, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Cardinal Health | Actinium-225, Gallium-67 / 68, Indium-111, Technetium-99, and Others | Carbon-11 / 14, Fluorine-18, Iodine-121 / 123 / 124 / 125 / 131, Xenon-133, and Others | Radioisotope | Accelerator and Others | Diagnostic Imaging, Therapeutic Application, and Research and Development | Diagnostic Centers, Hospitals, Academic and Research Institutes, and Radiopharmacies |
Recent Developments
In April 2026, the company announced the expansion of Actinium-225 production capacity with an aim to support growing demand for novel cancer therapies. The company also announced the appointment of Patricia Hemingway Hall as chair of the board in March 2026.
To know more about the recent initiatives of Cardinal Health and other medical isotope production companies, access full report.
3. China Isotope & Radiation Corporation
Company Overview
China Isotope & Radiation Corporation (CIRC), the flagship subsidiary of China National Nuclear Corporation, is a leading provider of nuclear technology applications in Asia with a strong focus on medical isotope in medicine. With a nationwide network of Radiopharmacies and a presence in nearly 20 cities, the company offers broad marketing and technical support across the radiopharmaceutical value chain. Its portfolio includes the engineering and installation of Cobalt-60 irradiation plants, as well as the supply of radioactive sources.
China Isotope & Radiation Corporation: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| China Isotope & Radiation Corporation | 1983 | China | 1,001-5,000 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by China Isotope & Radiation Corporation, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| China Isotope & Radiation Corporation | Cobalt-60, Gallium-67 / 68, Lutetium-177, Molybdenum-98 / 99 / 100, Technetium-99, and Iridium-192 | Carbon-11 / 14, Fluorine-18, Iodine-121 / 123 / 124 / 125 / 131, and Others | Stable isotope and Radioisotope | Accelerator and Nuclear Reactors | Diagnostic Imaging, Therapeutic Application, Research and Development, and Others | Diagnostic Centers, Hospitals, and Academic and Research Institutes |
Recent Developments
In March 2026, the company signed an exclusive agreement with the Spallation Neutron Source Science Center to accelerate China’s self-developed alpha radiopharmaceuticals transition from laboratory research to clinical application.
To know more about the recent initiatives of China Isotope & Radiation Corporation and other medical isotope production companies, access full report.
4. CMR Isotopes
Company Overview
CMR Isotopes delivers a comprehensive portfolio of medical isotopes, spanning diagnostic tracers, therapeutic radioisotopes, and beyond. In addition to radioisotopes, the company produces Oxygen-18-a critical stable isotope for PET diagnostics—as well as a broad range of stable and radioactive isotopes, peptides, and chemical kits. CMR also supplies generators for short-lived isotopes like Technetium-99m and Iodine-131, enabling efficient on-site production. Complementing its core offerings, CMR specializes in heavy water and deuterated compounds for NMR spectroscopy and research applications.
CMR Isotopes: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| CMR Isotopes | 2001 | Russia | 51-200 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by CMR Isotopes, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope in medicine.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| CMR Isotopes | Actinium-225, Gallium-67 / 68, Indium-111, Lutetium-177, and Technetium-99 | Fluorine-18, Iodine-121 / 123 / 124 / 125 / 131, and Others | Stable isotope and Radioisotope | Chemical Separation and Nuclear Reactors | Diagnostic Imaging, Therapeutic Application, and Research and Development | Diagnostic Centers, Hospitals, and Academic and Research Institutes |
Recent Developments
In June 2026, the company participated in the SNMMI Annual Meeting to showcase its latest innovations and solutions at the Los Angeles Convention Center.
To know more about the recent initiatives of CMR Isotopes and other medical isotope production companies, access full report.
5. Curium Pharma
Company Overview
Curium Pharma leads the global nuclear medicine sector by producing and distributing life-saving radioactive tracer key medical isotopes that reach patients worldwide. The company’s expertise centers on manufacturing essential isotopes for nuclear medicine applications. Curium prioritizes cancer therapies, with targeted development for Neuroendocrine Tumors and prostate cancer PSMA, leveraging our isotope production capabilities. The company is also integrating Artificial Intelligence to advance imaging technologies powered by our isotopes, empowering healthcare professionals with superior tools and insights.
Curium Pharma: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Curium Pharma | 2017 | US | 1,001-5000 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by Curium Pharma, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope in medicine.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Curium Pharma | Copper-61 / 64 / 67, Gallium-67 / 68, Indium-111, Lutetium-177, Molybdenum-98 / 99 / 100, Technetium-99, and Iridium-192 | Fluorine-18, Iodine-121 / 123 / 124 / 125 / 131, and Xenon-133 | Stable isotope and Radioisotope | Accelerator, Chemical Separation, Nuclear Reactors, and Others | Diagnostic Imaging, Therapeutic Application, Research and Development, and Others | Diagnostic Centers, Hospitals, Academic and Research Institutes, and Radiopharmacies |
Recent Developments
In February 2026, the company entered a strategic collaboration with PeptiDream and PDRadiopharma for the enrollment of first patient for clinical trials of 177Lu-PSMA-I&T. The company also received CDE approval for Investigational New Drug Application (IND) application for 177Lu-PSMA I&T in January 2026.
To know more about the recent initiatives of Curium Pharma and other medical isotope production companies, access full report.
6. Eckert & Ziegler
Company Overview
Eckert & Ziegler is a leading global provider of isotope technology, with a core emphasis on medical isotope production for nuclear medicine and scientific applications. The company excels in manufacturing radioactive medical devices, such as Iodine-125 seeds for prostate cancer brachytherapy and ocular applicators, alongside supplying diagnostic tools and radiopharmaceutical services to healthcare providers. Complementing this, it produces sealed radioactive sources for calibrating imaging equipment and industrial measurement devices. Through its customized Contract Manufacturing and Development Services from early-stage development to full commercialization—the company supports the lifecycle of isotope-based products.
Eckert & Ziegler: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Eckert & Ziegler | 1997 | Germany | 1,001-5000 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by Eckert & Ziegler, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope in medicine.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Eckert & Ziegler | Actinium-225, Cobalt-60, Copper-61 / 64 / 67, Gallium-67 / 68, Indium-111, Lutetium-177, Molybdenum-98 / 99 / 100, Lead-212, Technetium-99, Yttrium-90 / 176, and Iridium-192 | Carbon-11 / 14, Iodine-121 / 123 / 124 / 125 / 131, Xenon-133, and Others | Stable isotope and Radioisotope | Accelerator, Chemical Separation, Nuclear Reactors, and Others | Diagnostic Imaging, Therapeutic Application, Research and Development, and Others | Diagnostic Centers, Hospitals, Academic and Research Institutes, and Radiopharmacies |
Recent Developments
In April 2026, the company announced the achievement of patient access for Ru-106 by Medical Device Regulation. The company also entered a strategic collaboration with Molecular Partners for the development of targeted alpha radiotherapeutics in February 2026.
To know more about the recent initiatives of Eckert & Ziegler and other medical isotope production companies, access full report.
7. Eden Radioisotopes
Company Overview
Eden Radioisotopes is a pioneering radiopharmaceutical company dedicated to revolutionizing medical isotope production for cancer diagnostics and therapy. The company operates the nation's first commercial-scale medical radioisotope facility, leveraging cutting-edge cyclotron technology to produce high-purity isotopes. Eden addresses critical supply chain vulnerabilities by enabling domestic, on-demand manufacturing, reducing reliance on imports and ensuring reliable access for US healthcare providers. Their proprietary processes deliver isotopes with superior quality and yield. Eden's vertically integrated platform spans isotope production, compound development, and clinical translation. With recent FDA approvals and partnerships accelerating commercialization, Eden is poised to transform patient outcomes through scalable, sustainable isotope solutions.
Eden Radioisotopes: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Eden Radioisotopes | 2019 | US | 11-50 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by Eden Radioisotopes, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Eden Radioisotopes | Copper-61 / 64 / 67, Lutetium-177, Molybdenum-98 / 99 / 100, Yttrium-90 / 176, and Others | Iodine-121 / 123 / 124 / 125 / 131, Xenon-133, and Others | Radioisotope | Chemical Separation and Nuclear Reactors | Diagnostic Imaging and Therapeutic Application | Diagnostic Centers, Hospitals, and Radiopharmacies |
To know more about the recent initiatives of Eden Radioisotopes and other medical isotope production companies, access full report.
8. Global Medical Solutions
Company Overview
GMS is one-stop-shop network of specialized facilities for nuclear medicine departments. The company manages advanced Positron Emission Tomography cyclotrons for producing high-purity radiotracers, alongside manufacturing specialized cold kits, sterilized vials, and offering Contract Manufacturing Organization services for clinical trials. GMS's isotope portfolio extends to Technetium-99m generators, Gallium-68 for theranostics, and emerging options like copper-64 for targeted therapies, all produced in GMP-compliant facilities with just-in-time logistics to combat decay risks and global shortages, positioning GMS as a key innovator.
Global Medical Solutions: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Global Medical Solutions | 2003 | Australia | 201-500 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by Global Medical Solutions, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Global Medical Solutions | Actinium-225, Copper-61 / 64 / 67, Gallium-67 / 68, Lutetium-177, Technetium-99, and Yttrium-90 / 176 | Fluorine-18 and Iodine-121 / 123 / 124 / 125 / 131 | Radioisotope | Accelerator, Chemical Separation, and Nuclear Reactors | Diagnostic Imaging and Therapeutic Application | Diagnostic Centers, Hospitals, and Radiopharmacies |
To know more about the recent initiatives of Global Medical Solutions and other medical isotope production companies, access full report.
9. NorthStar Medical Radioisotopes
Company Overview
NorthStar Medical Radioisotopes is a commercial company specializing in the production of medical isotopes, with a particular focus on Actinium-225 and Copper-67 for the development of cancer therapeutics. The company also provides customized CDMO services to support biopharmaceutical partners across their development programs. Its integrated production infrastructure, including the Electron Accelerator Production Facility, allows NorthStar to manufacture multiple radioisotopes within the same site. By combining production, processing, development, and supply on a single campus, the company is able to deliver high-quality isotopes on a large scale. In addition, its regulatory and quality teams help ensure product safety and compliance throughout the manufacturing process.
NorthStar Medical Radioisotopes: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| NorthStar Medical Radioisotopes | 2006 | US | 201-500 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by NorthStar Medical Radioisotopes, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| NorthStar Medical Radioisotopes | Actinium-225, Copper-61 / 64 / 67, Indium-111, Lutetium-177, Molybdenum-98 / 99 / 100, Technetium-99, and Zirconium-89 | Iodine-121 / 123 / 124 / 125 / 131 | Stable isotope and Radioisotope | Accelerator, Chemical Separation, Nuclear Reactors, and Others | Diagnostic Imaging, Therapeutic Application, Research and Development, and Others | Diagnostic Centers, Hospitals, Academic and Research Institutes, Radiopharmacies, and Others |
Recent Developments
In April 2026, the company received FDA approval of the Drug master File for No-Carrier-Added Actinium-225. NorthStar also collaborated with BIOEMTECH for the strategic supply partnership of Actinium-225 in February 2026.
To know more about the recent initiatives of NorthStar Medical Radioisotopes and other medical isotope production companies, access full report.
10. Nusano
Company Overview
Nusano revolutionizes medical isotope production by integrating cutting-edge research from top-tier universities with its proprietary customized particle accelerator technology. The company ensures a reliable, global supply of these critical isotopes, preventing disruptions in life-saving therapeutics for patients worldwide. Leveraging its advanced particle beam technology, which can produce over 40 isotopes simultaneously, including up to 12 at once, Nusano enables the formulation of precision radiotherapeutics, particularly for high-impact cancer treatments. Through ongoing clinical trials, the company validates the safety and efficacy of these innovative drugs, bridging production excellence with real-world patient benefits.
Nusano: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| Nusano | 2016 | US | 51-200 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by Nusano, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| Nusano | Actinium-225, Copper-61 / 64 / 67, Gallium-67 / 68, Indium-111, Lutetium-177, Molybdenum-98 / 99 / 100, Lead-212, Technetium-99, Zirconium-89, Iridium-192, and Others | Fluorine-18 and Iodine-121 / 123 / 124 / 125 / 131 | Stable isotope and Radioisotope | Accelerator, Nuclear Reactors, and Others | Diagnostic Imaging, Therapeutic Application, and Research and Development | Diagnostic Centers, Hospitals, Academic and Research Institutes, and Others |
Recent Developments
In June 2026, the company announced the successful generation of a particle beam through its proprietary accelerator technology and named the milestone- Beam on Target’.
To know more about the recent initiatives of Nusano and other medical isotope production companies, access full report.
11. ROTOP Pharmaka
Company Overview
ROTOP Pharmaka is a manufacturer, and specializes in sterile lyophilizates, API, and reagents tailored for medical isotopes, all crafted under rigorous cGMP to ensure the highest quality and safety. At the core, the company prioritizes ethical development of cutting-edge medical isotope solutions that advance diagnostics, therapies, and patient care. ROTOP’s foundational values guide every operation, enabling strategic decisions and continuous innovation. The company actively catalyzes fresh ideas to enrich our portfolio, positioning ROTOP as a trusted leader in next-generation nuclear medicine. With decades of expertise, they supply key isotopes like molybdenum-99 and lutetium-177, supporting global radiopharmaceutical demands. The state-of-the-art facilities emphasize scalability and sustainability, partnering with leading pharma companies to accelerate isotope-based innovations from research to clinical application.
ROTOP Pharmaka: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| ROTOP Pharmaka | 2000 | Germany | 201-500 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by ROTOP, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| ROTOP Pharmaka | Actinium-225, Copper-61 / 64 / 67, Gallium-67 / 68, Indium-111, Lutetium-177, Lead-212, and Technetium-99 | Fluorine-18 and Iodine-121 / 123 / 124 / 125 / 131 | Radioisotope | Accelerator, Nuclear Reactors, and Others | Diagnostic Imaging, Therapeutic Application, and Research and Development | Diagnostic Centers, Hospitals, and Academic and Research Institutes |
Recent Developments
In April 2026, the company received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. In March 2026, the company appointed Dr. Michael Peterseim as its new Chief Financial Officer.
To know more about the recent initiatives of ROTOP Pharmaka and other medical isotope production companies, access full report.
12. SpectronRx
Company Overview
SpectronRx delivers comprehensive, end-to-end services for medical isotope production and theranostic drug development, tailored to your exact budget, timelines, and needs. With deep technical expertise in isotope manufacturing, the company provides high-quality results at every stage—from production to final product handling. Built-in redundancy across facilities ensures seamless, uninterrupted isotope supply for critical industries. The company’s White Glove Service treats every theranostic product with exceptional care, blending domain knowledge with an unwavering commitment to patient outcomes. Leveraging state-of-the-art facilities and cGMP-compliant processes, SpectronRx excels in producing high-purity medical isotopes for diagnostics and therapy. The company prioritizes innovation in radioisotope synthesis to accelerate clinical trials and commercialization.
SpectronRx: Company Overview
 |
Company Name | Year of establishment | Headquarters | Number of Employees |
| SpectronRx | 2004 | US | 51-200 |
List of Parameter Including Source of Isotopes, Type of Isotope, Type of Production Method, Application Area and End-user
The section provides information on various parameters like sources of isotope offered by offered by SpectronRx, along with details on the type of isotope, type of production method, application area, and end users dedicated to medical isotope production.
| Company | Source of Isotopes (Metals) | Source of Isotopes (Non-Metal) | Type of Isotope | Type of Production Method | Application Area | End-user |
| SpectronRx | Actinium-225, Copper-61 / 64 / 67, Gallium-67 / 68, Indium-111, Lutetium-177, Lead-212, and Zirconium-89 | Fluorine-18 and Iodine-121 / 123 / 124 / 125 / 131 | Stable isotope and Radioisotope | Accelerator and Nuclear Reactors | Diagnostic Imaging, Therapeutic Application, Research and Development, and Others | Diagnostic Centers, Hospitals, Academic and Research Institutes, and Radiopharmacies |
Recent Developments
In April 2026, the company secured an investment of $85 million from OrbiMed for the expansion of its medical isotope production facility. The company also announced an expansion of its Grissom Aeroplex campus to 34 Acres to increase the radiopharmaceutical manufacturing space in January 2026.
To know more about the recent initiatives of SpectronRx and other medical isotope production companies, access full report.
What About Other Medical Isotope Production Companies Around the World?
The above article features the leading medical isotope production companies selected from a pool of around 110 companies that we have compiled. If you're interested, you can download Sample Report the on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.